Alnylam Pharmaceuticals Inc (ALNY)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
10/100
Low signalSIGNAL SCORE
P(beat S&P 500 · next 20 sessions)45%
Our last 30 days of resolved calls came true 29% of the time.See the track record →
Price
$239.36
1 day
+0.46%
1 week
-7.65%
1 month
-1.01%
1 year
-48.33%
Market cap
$32.1B
Company fundamentals
P/E (TTM)
39.7×
EPS (TTM)
$5.88
Debt / Equity
2.02
Current ratio
3.05
Operating margin
19.9%
Net margin
16.8%
Gross margin
79.7%
Return on equity
93.6%
Revenue growth (YoY)
95.1%
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
Example trade plan · illustrative risk framework
Entry zone
$235.77–$244.15
Stop-loss (exit)
$215.42 −10%
Target (exit)
$287.23 +20%
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
Why it ranks: factor attribution
- QualityRevenue growing 95% y/y+10
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →